Mini-allografting to complement treatment with glivec (Imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in chronic myeloid leukaemia (CML) patients aged 65 years and under with matched sibling donors

Mini-allografting to complement treatment with glivec (Imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in chronic myeloid leukaemia (CML) patients aged 65 years and under with matched sibling donors: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86187144

Enrollment

Registered

2004-09-30

Start date

2002-11-30

Completion date

Unknown

Last updated

2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukaemia Cancer Myeloid leukaemia

Interventions

Patients will be given imatinib for 6 - 12 months with dose increases to 600 mg for poor response. Reduced intensity allograft with peripheral blood stem cells (PBSC) after fludarabine, melphelan and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 65 years and under 2. A diagnosis of chronic myeloid leukaemia 3. Attending the Haematology Out-patients' clinic 4. Fulfill the eligibility criteria

Exclusion criteria

Exclusion criteria: Does not comply with the above inclusion criteria

Design outcomes

Primary

Measure	Time frame
Survival and remission status at six months and one year post-transplant.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 5, 2026